semaglutide things to know Take a few moments hear from our Medical Director, Dr Berry, as he breaks down (GLP-1s, Wegovy, Ozempic, etc.) and what he wants Patients to about the popular weight loss drug Everything You Need to Know

Retatrutide has no MHRA or EMA marketing authorisation, and obtaining or using it outside an MHRA-authorised clinical trial is inappropriate and may be unlawful in the UK

Comments (5) Effective July 1, health insurer Cigna (CI) will no longer cover GLP-1 weight-loss drugs such as Novo Nordisks (NVO) Wegovy and Eli Lillys (LLY) Zepbound in its employee health plan, Reuters reported, citing internal company communications

Because of its widespread popularity as a weight loss drug, and recent popular sedation due to celebrity endorsements, semaglutide medications like Ozempic have fallen in short supply

Schedule a telehealth consultation with GoalBMI Wellness